Piper Jaffray raised its rating on Watson Pharmaceuticals WPI from Neutral to Overweight and increased its price target from $77 to $103.
Piper Jaffray noted, "With favorable competitive dynamics for an extended period likely for Concerta, Adderall XR (AXR) and Lidoderm, plus attractive synergies from the Actavis purchase and optionality on other generic opportunities (e.g. Intuniv, OxyContin), we believe WPI's current one-year forward P/E of 11x (on our EPS estimate of $8.22) is sustainable. In that context, we believe the risk/reward profile for WPI shares is attractive. We are upgrading WPI to an Overweight from a Neutral and raising our price target to $103 from $77, reflecting upward revisions to our estimates and a higher multiple."
Watson Pharmaceuticals closed at $87.71 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in